Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.

Michael B LivingstonMegan H Jagosky Myra M RobinsonWilliam A AhrensJennifer H BenbowCarol J FarhangfarDavid M FoureauDeirdre M MaxwellEmily A BaldrigeXhevahire BegicJames T SymanowskiNury M SteuerwaldColin J AndersonJoshua C PattJeffrey S KneislEdward S Kim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Combination pembrolizumab and doxorubicin has manageable toxicity and preliminary promising activity in treatment of patients with anthracycline-naive advanced STS.

Keyphrases

phase ii study
locally advanced
drug delivery
squamous cell carcinoma
advanced non small cell lung cancer
open label
cancer therapy
small cell lung cancer
rectal cancer
oxidative stress
randomized controlled trial
combination therapy
liver metastases
oxide nanoparticles